Cheng Liu - 30 Oct 2024 Form 4 Insider Report for Estrella Immunopharma, Inc. (ESLA)

Role
Chief Executive Officer, Director
Signature
/s/ Cheng Liu
Issuer symbol
ESLA
Transactions as of
30 Oct 2024
Transactions value $
$0
Form type
4
Filing time
14 Feb 2025, 16:30:20 UTC
Previous filing
10 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESLA Incentive Share Option Award +491K 491K 30 Oct 2024 Common Stock 491K $0.82 Direct F1, F3
transaction ESLA Nonstatutory Share Option Award +509K 509K 30 Oct 2024 Common Stock 509K $0.82 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares.
F2 The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.
F3 On October 30, 2024, the Board of the Company awarded Mr. Liu a nonstatutory shares option grant of 509,204 shares.
F4 The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.